Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.9K
Overview
51.9K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.0K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.6K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

651
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
651
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Factors Involved in Tuberculosis Recurrence in a Low-incidence Setting; Reactivation Predominates Over Reinfection in a 30-year Surveillance Study.

Open forum infectious diseases·2026
Same author

Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Recommendations for Performing Spirometry.

Archivos de bronconeumologia·2026
Same author

Exploiting the Biorefinery Potential of Spent Mushroom Substrate: The Time to Do It Is Now.

Molecules (Basel, Switzerland)·2025
Same author

A novel use of temporary ICL during DMEK to prevent gas-induced opacification of a scleral-fixated Carlevale IOL.

American journal of ophthalmology case reports·2025

Related Experiment Video

Updated: Feb 12, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K

Vaccination against tuberculosis.

Carlos Martin1, Nacho Aguilo2, Jesús Gonzalo-Asensio1

  • 1Grupo de Genética de Micobacterias, Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, España; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, España; Servicio de Microbiología, Hospital Universitario Miguel Servet, ISS Aragón, Zaragoza, España.

Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|April 9, 2018
PubMed
Summary

Bacille Calmette-Guérin (BCG) vaccination offers limited protection against pulmonary tuberculosis. MTBVAC, a novel live-attenuated Mycobacterium tuberculosis vaccine, is under clinical evaluation as a potential BCG replacement for improved tuberculosis prevention.

Keywords:
BCGMTBVACTuberculosis vaccineVacuna tuberculosis

More Related Videos

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

641

Related Experiment Videos

Last Updated: Feb 12, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

641

Area of Science:

  • Immunology and infectious diseases
  • Vaccinology
  • Microbiology

Background:

  • Bacille Calmette-Guérin (BCG) vaccination is a global standard for tuberculosis prevention, covering nearly 90% of newborns.
  • While effective against disseminated tuberculosis, BCG provides limited protection against pulmonary tuberculosis, the primary form responsible for disease transmission.
  • There is a critical need for novel tuberculosis vaccines that offer improved and broader protection, particularly against respiratory forms of the disease.

Purpose of the Study:

  • To evaluate MTBVAC, a live-attenuated Mycobacterium tuberculosis vaccine candidate, for its potential to prevent tuberculosis.
  • To position MTBVAC as a potential replacement for BCG in newborn immunization schedules.
  • To explore MTBVAC's efficacy in adolescents and adults previously vaccinated with BCG as a secondary objective.

Main Methods:

  • Clinical evaluation of MTBVAC, a live-attenuated Mycobacterium tuberculosis vaccine.
  • Targeting tuberculosis prevention in newborns as a primary strategy.
  • Assessing MTBVAC in BCG-vaccinated adolescents and adults.

Main Results:

  • MTBVAC is the first and only live-attenuated Mycobacterium tuberculosis vaccine candidate currently in clinical evaluation.
  • Clinical development is underway to assess its efficacy and safety profile.
  • Immunological responses and the nature of long-lived immunity induced by MTBVAC are key areas of investigation.

Conclusions:

  • MTBVAC represents a promising novel vaccine candidate for tuberculosis prevention.
  • Its development aims to address the limitations of current BCG vaccination, particularly against pulmonary tuberculosis.
  • Further clinical evaluation is essential to establish MTBVAC's role in global tuberculosis control strategies.